Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.

Cell-based therapies in pulmonary hypertension: who, what, and when?

Majka S, Burnham E, Stenmark KR.

Am J Physiol Lung Cell Mol Physiol. 2011 Jul;301(1):L9-L11. doi: 10.1152/ajplung.00118.2011. Epub 2011 Apr 22. No abstract available.

2.

Endothelial progenitor cell-based therapy for pulmonary arterial hypertension.

Yang JX, Pan YY, Zhao YY, Wang XX.

Cell Transplant. 2013;22(8):1325-36. doi: 10.3727/096368912X659899. Epub 2013 Jan 2. Review.

PMID:
23295102
3.

Endothelial progenitors in pulmonary hypertension: new pathophysiology and therapeutic implications.

Fadini GP, Avogaro A, Ferraccioli G, Agostini C.

Eur Respir J. 2010 Feb;35(2):418-25. doi: 10.1183/09031936.00112809. Review.

4.

Innate immunity in the therapeutic actions of endothelial progenitor cells in pulmonary hypertension.

Ormiston ML, Deng Y, Stewart DJ, Courtman DW.

Am J Respir Cell Mol Biol. 2010 Nov;43(5):546-54. doi: 10.1165/rcmb.2009-0152OC. Epub 2009 Dec 7.

PMID:
19995942
5.

Current status of cell therapy for systemic arterial hypertension.

Silva VJ, Machado MP, Voltarelli JC.

Expert Rev Cardiovasc Ther. 2009 Nov;7(11):1307-11. doi: 10.1586/erc.09.110. No abstract available.

PMID:
19900013
6.

Identification of putative endothelial progenitor cells (CD34+CD133+Flk-1+) in endarterectomized tissue of patients with chronic thromboembolic pulmonary hypertension.

Yao W, Firth AL, Sacks RS, Ogawa A, Auger WR, Fedullo PF, Madani MM, Lin GY, Sakakibara N, Thistlethwaite PA, Jamieson SW, Rubin LJ, Yuan JX.

Am J Physiol Lung Cell Mol Physiol. 2009 Jun;296(6):L870-8. doi: 10.1152/ajplung.90413.2008. Epub 2009 Mar 13.

7.

MicroRNAs and mesenchymal stem cells: hope for pulmonary hypertension.

Zhu Z, Fang Z, Hu X, Zhou S.

Rev Bras Cir Cardiovasc. 2015 Jul-Sep;30(3):380-5. doi: 10.5935/1678-9741.20150033. Review.

8.

Endothelial progenitor cells may inhibit apoptosis of pulmonary microvascular endothelial cells: new insights into cell therapy for pulmonary arterial hypertension.

Xia L, Fu GS, Yang JX, Zhang FR, Wang XX.

Cytotherapy. 2009;11(4):492-502. doi: 10.1080/14653240902960460.

PMID:
19526390
9.

VEGF ameliorates pulmonary hypertension through inhibition of endothelial apoptosis in experimental lung fibrosis in rats.

Farkas L, Farkas D, Ask K, Möller A, Gauldie J, Margetts P, Inman M, Kolb M.

J Clin Invest. 2009 May;119(5):1298-311. doi: 10.1172/JCI36136. Epub 2009 Apr 20.

10.

Prevalence of anti-endothelial cell antibodies in idiopathic pulmonary arterial hypertension.

Arends SJ, Damoiseaux J, Duijvestijn A, Debrus-Palmans L, Boomars K, Broers B, Tervaert JW, van Paassen P.

Eur Respir J. 2010 Apr;35(4):923-5. doi: 10.1183/09031936.00164209. No abstract available.

11.

Cellular and molecular basis of pulmonary arterial hypertension.

Morrell NW, Adnot S, Archer SL, Dupuis J, Jones PL, MacLean MR, McMurtry IF, Stenmark KR, Thistlethwaite PA, Weissmann N, Yuan JX, Weir EK.

J Am Coll Cardiol. 2009 Jun 30;54(1 Suppl):S20-31. doi: 10.1016/j.jacc.2009.04.018. Review.

12.

Improved cell survival and paracrine capacity of human embryonic stem cell-derived mesenchymal stem cells promote therapeutic potential for pulmonary arterial hypertension.

Zhang Y, Liao S, Yang M, Liang X, Poon MW, Wong CY, Wang J, Zhou Z, Cheong SK, Lee CN, Tse HF, Lian Q.

Cell Transplant. 2012;21(10):2225-39. doi: 10.3727/096368912X653020. Epub 2012 Jul 5.

PMID:
22776744
13.

Regenerative pulmonary medicine: potential and promise, pitfalls and challenges.

Anversa P, Perrella MA, Kourembanas S, Choi AM, Loscalzo J.

Eur J Clin Invest. 2012 Aug;42(8):900-13. doi: 10.1111/j.1365-2362.2012.02667.x. Epub 2012 Mar 21. Review.

14.

Mesenchymal stem cell-based therapy: Bench to Bedside.

Kami D, Gojo S, Umezawa A.

Rinsho Ketsueki. 2013 May;54(5):436-43. Review. No abstract available.

PMID:
23727681
15.

Endothelial progenitor cells in pulmonary hypertension - dawn of cell-based therapy?

Toshner M, Morrell NW.

Int J Clin Pract Suppl. 2010 Jan;(165):7-12. doi: 10.1111/j.1742-1241.2009.02232.x. Review.

PMID:
19958395
16.

Cell-based gene transfer of vascular endothelial growth factor attenuates monocrotaline-induced pulmonary hypertension.

Campbell AI, Zhao Y, Sandhu R, Stewart DJ.

Circulation. 2001 Oct 30;104(18):2242-8.

17.

[Bone and Stem Cells. Isolation and immunomodulation of mesenchymal stem cells].

Matsuzaki Y, Sato Y.

Clin Calcium. 2014 Apr;24(4):575-83. doi: CliCa1404575583. Review. Japanese.

PMID:
24681504
18.

Increased pericyte coverage mediated by endothelial-derived fibroblast growth factor-2 and interleukin-6 is a source of smooth muscle-like cells in pulmonary hypertension.

Ricard N, Tu L, Le Hiress M, Huertas A, Phan C, Thuillet R, Sattler C, Fadel E, Seferian A, Montani D, Dorfmüller P, Humbert M, Guignabert C.

Circulation. 2014 Apr 15;129(15):1586-97. doi: 10.1161/CIRCULATIONAHA.113.007469. Epub 2014 Jan 30.

19.

Exosomes: cell garbage can, therapeutic carrier, or trojan horse?

Thébaud B, Stewart DJ.

Circulation. 2012 Nov 27;126(22):2553-5. doi: 10.1161/CIRCULATIONAHA.112.146738. Epub 2012 Oct 31. No abstract available.

20.

GAPDH is critical for superior efficacy of female bone marrow-derived mesenchymal stem cells on pulmonary hypertension.

Tan R, Li J, Peng X, Zhu L, Cai L, Wang T, Su Y, Irani K, Hu Q.

Cardiovasc Res. 2013 Oct 1;100(1):19-27. doi: 10.1093/cvr/cvt165. Epub 2013 Jun 25.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk